Acquisition Pending

Eli Lilly and Company acquisition of LimmaTech Biologics AG

US$780m consideration

Announced May 2026

Advisers

Target
LimmaTech Biologics AG
Acquirer
Eli Lilly and Company
Target based in
Switzerland
Buyer based in
United States
Sector
Biotech

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.